Antares Pharma to Present at the Jefferies London Healthcare Conference
November 10, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
November 04, 2021 07:00 ET
|
Antares Pharma, Inc.
Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares...
Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
October 28, 2021 08:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board...
Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA
October 25, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous...
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
October 21, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021...
Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
October 18, 2021 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that it entered into an exclusive license...
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
September 30, 2021 09:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for...
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
August 05, 2021 07:00 ET
|
Antares Pharma, Inc.
Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares...
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
July 28, 2021 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021...